VIDEO: Daunorubicin 60 mg/m2 may be favored in AML induction therapy dose debate
NEW ORLEANS — In this video perspective, Aaron T. Gerds, MD, MS, discusses a study presented at the ASH Annual Meeting and Exposition comparing daunorubicin regimens for patients with newly diagnosed acute myeloid leukemia.
"This study randomized folks between 90 mg/m2 and 60 mg/m2 of daunorubicin and it turned out 60 mg/m2 wasn't any worse," Gerds said, noting, however, that 60 mg/m2 may be associated with more toxicity.
The debate over the right dose of daunorubicin for induction chemotherapy has long been ongoing, according to Gerds, assistant professor at the Cleveland Clinic Taussig Cancer Institute.
This whole question of 90 mg/m2 vs. 60 mg/m2 is incredibly important to know going forward, particularly since some patients have FLT3 mutations, and the RATIFY trial, which led to the use of midostaurin in this situation, only had daunorubicin doses of 60 mg/m2 in it. So we can now streamline our practices based on these results,” he said.
Reference:
- Röllig C, et al. Abstract 217. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Collapse
Healio Interviews